Ancora Heart Reports 12 Month Results of AccuCinch System for the Treatment of Patients with Heart Failure
- The company highlighted the 12mos. results of AccuCinch System from 51 symptomatic heart failure patients with reduced ejection fraction (HFrEF)
- The results showed a significant and progressive improvement in left ventricular end-diastolic volume (LVEDV) @12mos. over baseline. The system also showed a significant and sustained improvement in overall quality of life scores (KCCQ-OS), functional capacity (6MWT distances), NYHA classification, and ejection fraction @12mos.
- The 12mos. results were presented at THT 2023 and published in the Journal of Cardiac Failure. AccuCinch System is currently being studied in the (CORCINCH-HF) study in 400 patients for HFrEF
Ref: Businesswire | Image: Ancora Heart
Related News:- NICE Failed to Recommend Boehringer Ingelheim and Lilly’s Jardiance (empagliflozin) for Heart Failure
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].